Expert Insights for Hematology/Oncology Pharmacists on Later-Generation TKIs as Frontline Therapy in Chronic-Phase CML

Hematologists and oncologists will be able to recommend personalized treatment strategies that include later-generation tyrosine kinase inhibitors as frontline therapy for patients with chronic-phase CML after reviewing recent clinical evidence on their use to improve patient outcomes and increase the likelihood of treatment-free remission through an on-demand webcast, ClinicalThought commentary, and accompanying downloadable slides.

Share

Program Content

Events

  • Live Event Expert Insights for Hematology/Oncology Pharmacists on Later-Generation TKIs as Frontline Therapy in Chronic-Phase CML
    Expert Insights for Hematology/Oncology Pharmacists on Later-Generation TKIs as Frontline Therapy in Chronic-Phase CML
    Congratulations: You achieved a completion on 04/09/2022

    You can enroll in the following live event(s) on this topic.

Activities

Frontline CML Therapy and Risk Assessment
The Role of the Hematology Pharmacist in CP-CML: Brief Overview on Individualizing Frontline Therapy, Risk Assessment, and Monitoring
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 23, 2025

Expires: October 22, 2025

Pharmacist Role in Monitoring CP CML Treatment
Pharmacist Role: Monitoring Responses to CP-CML Therapy
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 24, 2025

Expires: October 23, 2025

New Frontline CP CML Data
Integrating New Frontline Data Into CP-CML Clinical Practice
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 24, 2025

Expires: October 23, 2025

Provided by

ProCE Banner

Provided by ProCE LLC, in partnership with Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Partners

Clinical Care Options, LLC

ProCE Banner